Boyle Kevin S. Sr. - Net Worth and Insider Trading

Boyle Kevin S. Sr. Net Worth

The estimated net worth of Boyle Kevin S. Sr. is at least $11,013 dollars as of 2024-11-05. Boyle Kevin S. Sr. is the CEO of Alaunos Therapeutics Inc and owns about 5,322 shares of Alaunos Therapeutics Inc (TCRT) stock worth over $11,013. Details can be seen in Boyle Kevin S. Sr.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Boyle Kevin S. Sr. has not made any transactions after 2023-09-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Boyle Kevin S. Sr.

Boyle Kevin S. Sr. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Boyle Kevin S. Sr. owns 1 companies in total, including Alaunos Therapeutics Inc (TCRT) .

Click here to see the complete history of Boyle Kevin S. Sr.’s form 4 insider trades.

Insider Ownership Summary of Boyle Kevin S. Sr.

Ticker	Comapny	Transaction Date	Type of Owner
TCRT	Alaunos Therapeutics Inc	2023-09-01	director & Chief Executive Officer

Boyle Kevin S. Sr. Latest Holdings Summary

Boyle Kevin S. Sr. currently owns a total of 1 stock. Boyle Kevin S. Sr. owns 5,322 shares of Alaunos Therapeutics Inc (TCRT) as of September 1, 2023, with a value of $11,013.

Latest Holdings of Boyle Kevin S. Sr.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TCRT	Alaunos Therapeutics Inc	2023-09-01	5,322	2.07	11,013

Holding Weightings of Boyle Kevin S. Sr.

Boyle Kevin S. Sr. Form 4 Trading Tracker

According to the SEC Form 4 filings, Boyle Kevin S. Sr. has made a total of 2 transactions in Alaunos Therapeutics Inc (TCRT) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Alaunos Therapeutics Inc is the sale of 453 shares on September 1, 2023, which brought Boyle Kevin S. Sr. around $9,522.

Insider Trading History of Boyle Kevin S. Sr.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Boyle Kevin S. Sr. Trading Performance

GuruFocus tracks the stock performance after each of Boyle Kevin S. Sr.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Boyle Kevin S. Sr. is -39.87%. GuruFocus also compares Boyle Kevin S. Sr.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Boyle Kevin S. Sr. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Boyle Kevin S. Sr.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Boyle Kevin S. Sr.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-0.74
Relative Return to S&P 500(%)	0.71

Boyle Kevin S. Sr. Ownership Network

Ownership Network List of Boyle Kevin S. Sr.

No Data

Ownership Network Relation of Boyle Kevin S. Sr.

Boyle Kevin S. Sr. Owned Company Details

What does Alaunos Therapeutics Inc do?

Who are the key executives at Alaunos Therapeutics Inc?

Boyle Kevin S. Sr. is the director & Chief Executive Officer of Alaunos Therapeutics Inc. Other key executives at Alaunos Therapeutics Inc include VP & Finance Michael Wong , See Remarks Abhishek K Srivastava , and VP & Research & Development Drew Deniger .

Alaunos Therapeutics Inc (TCRT) Insider Trades Summary

Over the past 18 months, Boyle Kevin S. Sr. made 1 insider transaction in Alaunos Therapeutics Inc (TCRT) with a net sale of 68,014.

In summary, during the past 3 months, insiders sold 0 shares of Alaunos Therapeutics Inc (TCRT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 453 shares of Alaunos Therapeutics Inc (TCRT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 453 shares.

Alaunos Therapeutics Inc (TCRT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alaunos Therapeutics Inc Insider Transactions

No Available Data

Boyle Kevin S. Sr. Mailing Address

Above is the net worth, insider trading, and ownership report for Boyle Kevin S. Sr.. You might contact Boyle Kevin S. Sr. via mailing address: C/o Ziopharm Oncology, Inc., One First Avenue, Parris Bldg 34, Boston Ma 02129.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.